Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB

Clinical Infectious Diseases

Volumn 48, Issue 5, 2009, Pages

  Chan, Edward D ^a   Strand, Matthew J ^a   Iseman, Michael D ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COMPARATIVE STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PROGNOSIS; SPUTUM CULTURE; TREATMENT OUTCOME; COHORT ANALYSIS;

ANTITUBERCULAR AGENTS; COHORT STUDIES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; HUMANS; PROGNOSIS; STREPTOMYCIN; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 60549100405     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597010     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
2. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81:430-2.
3. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
4. Raviglione MC, Smith IM. XDR tuberculosis - implications for global public health. N Engl J Med 2007; 356:656-9.
5. World Health Organization. Global map and information on XDRTB. 2008. Available at: http://www.who.int/tb/challenges/xdr/en/index.html. Accessed 10 October 2008.
6. Centers for Disease Control and Prevention. Extensively drug-resistant tuberculosis - United States, 1993-2006. MMWR Morb Mortal Wkly Rep 2007; 56:250-3.
7. Raviglione M. XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis 2006; 10:1185-7.
8. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169:1103-9.
9. Chan ED, Strand MJ, Iseman MD. XDR-TB is associated with significantly worse treatment outcomes than MDR-TB. N Engl J Med 2008; 359:657-9.
10. Chan ED, Chatterjee D, Iseman MD, Heifets LB. Pyrazinamide, ethambutol, ethionamide, and aminoglycosides. In: Rom WN, Garay SM, eds. Tuberculosis. Philadelphia: LippincottWilliams andWilkins, 2004:773-89.
11. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31:1155-9.
12. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl JMed 2008; 359:563-74.